Selected article for: "multidrug resistant bacteria and vitro study"
Author: Nguyen, Le Phuong; Park, Chul Soon; Pinto, Naina Adren; Lee, Hyunsook; Seo, Hyun Soo; Vu, Thao Nguyen; Mai, Hung; Pham, An H. T.; Jang, Eris; Cho, Young Lag; Goglin, Karrie; Nguyen, Kevin; White, Richard; D’Souza, Roshan; Fouts, Derrick E.; Yong, Dongeun
Title: In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and LCB10-0200/Avibactam, against Carbapenem-Resistant Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa Strains at a Tertiary Hospital in Korea
  • Cord-id: hh7vp5ry
  • Document date: 2021_4_16
    • ID: hh7vp5ry
    Snippet: The siderophore–antibiotic conjugate LCB10-0200 (a.k.a. GT-1) has been developed to combat multidrug-resistant Gram-negative bacteria. In this study, the in vitro activity of LCB10-0200 and LCB10-0200/avibactam (AVI) has been investigated against carbapenem-resistant Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Minimal inhibitory concentrations (MICs) of LCB10-0200, LCB10-0200/AVI, aztreonam, aztreonam/AVI, ceftazidime, ceftazidime/AVI, and mero
    Document: The siderophore–antibiotic conjugate LCB10-0200 (a.k.a. GT-1) has been developed to combat multidrug-resistant Gram-negative bacteria. In this study, the in vitro activity of LCB10-0200 and LCB10-0200/avibactam (AVI) has been investigated against carbapenem-resistant Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Minimal inhibitory concentrations (MICs) of LCB10-0200, LCB10-0200/AVI, aztreonam, aztreonam/AVI, ceftazidime, ceftazidime/AVI, and meropenem were measured using the agar dilution method. Whole genome sequencing was performed using Illumina and the resistome was analyzed. LCB10-0200 displayed stronger activity than the comparator drugs in meropenem-resistant E. coli and K. pneumoniae, and the addition of AVI enhanced the LCB10-0200 activity to MIC ≤ 0.12 mg/L for 90.5% of isolates. In contrast, whereas LCB10-0200 alone showed potent activity against meropenem-resistant A. baumannii and P. aeruginosa at MIC ≤ 4 mg/L for 84.3% of isolates, the combination with AVI did not improve its activity. LCB10-0200/AVI was active against CTX-M-, SHV-, CMY-, and KPC- producing E. coli and K. pneumoniae, while LCB10-0200 alone was active against ADC-, OXA-, and VIM- producing A. baumannii and P. aeruginosa. Both LCB10-0200 and LCB10-0200/AVI displayed low activity against IMP- and NDM- producing strains. LCB10-0200 alone exhibited strong activity against selected strains. The addition of AVI significantly increased LCB10-0200 activity against carbapenem-resistant E. coli, K. pneumoniae.

    Search related documents:
    Co phrase search for related documents
    • abdominal infection and lung infection: 1, 2, 3
    • acinetobacter baumannii and lung infection: 1, 2, 3
    • acinetobacter baumannii and machine learning: 1, 2
    • acinetobacter spp and machine learning: 1
    • activity improve and low activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • activity improve and lung infection: 1, 2
    • activity improve and machine learning: 1, 2
    • low activity and lung infection: 1, 2
    • low activity and machine learning: 1, 2, 3, 4
    • lung infection and machine learning: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23